The above-mentioned shows that HT can downregulate NFkB and it could decrease TNF-alfa and TGF-b levels as described for other antioxidant agents, such as silymarin in rat liver injury induced by CCl4 [36] causing a decrease in plasma levels of TIMP-1 in women with breast cancer. This evidence concerns the gene NFKB1 and breast carcinoma.